Vivus - Company & Market Research Reports

VIVUS is a biopharmaceutical company that develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company’s lead product Qsymia is a combination appetite suppressant/stimulant and seizure medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight and obese adults. VIVUS was founded in 1991 and is headquartered in Campbell, California.


Global Lifestyle Drugs Market 2017-2021 - Product Thumbnail Image

Global Lifestyle Drugs Market 2017-2021

  • Report
  • 91 Pages
From
Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023 - Product Thumbnail Image

Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023

  • Report
  • 71 Pages
From
Obesity Drugs and Therapies: Technologies and Global Markets - Product Thumbnail Image

Obesity Drugs and Therapies: Technologies and Global Markets

  • Report
From
Global Diabetes and Obesity Drugs Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Diabetes and Obesity Drugs Market Analysis 2016 - Forecast to 2022

  • Report
  • 141 Pages
From
Anti-Obesity Prescription Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 - Product Thumbnail Image

Anti-Obesity Prescription Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

  • Report
  • 100 Pages
From
Qsymia 2016 U.S Promotional Report - Product Thumbnail Image

Qsymia 2016 U.S Promotional Report

  • Report
  • 26 Pages
From
Anti-Obesity Drugs - Global Strategic Business Report - Product Thumbnail Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • 135 Pages
From
Global Anti-Obesity Drugs Market - Growth, Trends & Forecast 2017 - 2022 - Product Thumbnail Image

Global Anti-Obesity Drugs Market - Growth, Trends & Forecast 2017 - 2022

  • Report
  • 205 Pages
From
Obesity - Pipeline Review, H2 2017 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2017

  • Report
  • 518 Pages
From
U.S. Markets for Obesity Drugs & Devices - Product Thumbnail Image

U.S. Markets for Obesity Drugs & Devices

  • Report
  • 176 Pages
From
Generic Drug Opportunity Assessment - Avanafil (Stendra) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Avanafil (Stendra)

  • Report
From
Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018 - Product Thumbnail Image

Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

  • Report
  • 118 Pages
From
PDE Inhibitors Market, 2016-2026 - Product Thumbnail Image

PDE Inhibitors Market, 2016-2026

  • Report
  • 223 Pages
From
Alzheimer's Drugs Market, 2012 - 2017 - Product Thumbnail Image

Alzheimer's Drugs Market, 2012 - 2017

  • Report
  • 117 Pages
From
Oral Proteins and Peptides Market (3rd Edition), 2018-2030 - Product Thumbnail Image

Oral Proteins and Peptides Market (3rd Edition), 2018-2030

  • Report
  • 421 Pages
From
Contract Manufacturing in Pharmaceutical Industry, 2015-2025 - Product Thumbnail Image

Contract Manufacturing in Pharmaceutical Industry, 2015-2025

  • Report
  • 319 Pages
From
Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030 - Product Thumbnail Image

Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030

  • Report
  • 443 Pages
From
Erectile Dysfunction Market - Global Outlook and Forecast 2018-2023 - Product Thumbnail Image

Erectile Dysfunction Market - Global Outlook and Forecast 2018-2023

  • Report
  • 182 Pages
From
Global Infertility Diagnosis and Treatment Market Research and Forecast, 2018-2023 - Product Thumbnail Image

Global Infertility Diagnosis and Treatment Market Research and Forecast, 2018-2023

  • Report
From
World Erectile Dysfunction Drugs Market - Opportunities and Forecasts, 2017 - 2023 - Product Thumbnail Image

World Erectile Dysfunction Drugs Market - Opportunities and Forecasts, 2017 - 2023

  • Report
From
Loading Indicator
adroll